SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

# WBSCR17 siRNA (m): sc-155246

SANTA CRUZ BIOTECHNOLOGY

*The Power to Question*

## BACKGROUND

Williams-Beuren syndrome (WBS) is an autosomal dominant genetic condition that is characterized by physical, cognitive and behavioral traits. The physical traits associated with WBS include facial dysmorphology, vascular stenoses, growth deficiencies, dental anomalies and neurologic and musculoskeletal abnormalities. WBSCR17 (Williams-Beuren syndrome chromosomal region 17 protein), also known as putative polypeptide N-acetylgalactosaminyltransferase-like protein 3, polypeptide GalNAc transferase-like protein 3, or GALNTL3, is a 598 amino acid single-pass type II membrane protein belonging to the glycosyltransferase 2 family and GalNAc-T subfamily. Containing one ricin B-type lectin domain, WBSCR17 localizes to Golgi apparatus membrane and is highly expressed in brain and heart. Utilizing manganese and calcium as cofactors, WBSCR17 may catalyze the initial reaction in O-linked oligosaccharide biosynthesis.

## REFERENCES


1. Pagon, R.A., Bennett, F.C., LaVeck, B., Stewart, K.B. and Johnson, J. 1987. Williams syndrome: features in late childhood and adolescence. Pediatrics 80: 85-91.
2. Morris, C.A., Demsey, S.A., Leonard, C.O., Dilts, C. and Blackburn, B.L. 1988. Natural history of Williams syndrome: physical characteristics. J. Pediatr. 113: 318-326.
3. Dilts, C.V., Morris, C.A. and Leonard, C.O. 1990. Hypothesis for development of a behavioral phenotype in Williams syndrome. Am. J. Med. Genet. Suppl. 6: 126-131.
4. Lashkari, A., Smith, A.K. and Graham, J.M. 1999. Williams-Beuren syndrome: an update and review for the primary physician. Clin. Pediatr. 38: 189-208.
5. Bellugi, U., Lichtenberger, L., Mills, D., Galaburda, A. and Korenberg, J.R. 1999. Bridging cognition, the brain and molecular genetics: evidence from Williams syndrome. Trends Neurosci. 22: 197-207.
6. Merla, G., Ucla, C., Guipponi, M. and Reymond, A. 2002. Identification of additional transcripts in the Williams-Beuren syndrome critical region. Hum. Genet. 110: 429-438.
7. Hillier, L.W., Fulton, R.S., Fulton, L.A., Graves, T.A., Pepin, K.H., Wagner-McPherson, C., Layman, D., Maas, J., Jaeger, S., Walker, R., Wylie, K., Sekhon, M., Becker, M.C., O'Laughlin, M.D., et al. 2003. The DNA sequence of human chromosome 7. Nature 424: 157-164.
8. Gerhard, D.S., Wagner, L., Feingold, E.A., Shenmen, C.M., Grouse, L.H., Schuler, G., Klein, S.L., Old, S., Rasooly, R., Good, P., Guyer, M., Peck, A.M., Derge, J.G., Lipman, D., Collins, F.S., Jang, W., Sherry, S., et al. 2004. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 14: 2121-2127.


## PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

## CHROMOSOMAL LOCATION

Genetic locus: Wbscr17 (mouse) mapping to 5 G2.

## PRODUCT

WBSCR17 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see WBSCR17 shRNA Plasmid (m): sc-155246-SH and WBSCR17 shRNA (m) Lentiviral Particles: sc-155246-V as alternate gene silencing products.

For independent verification of WBSCR17 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-155246A, sc-155246B and sc-155246C.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## APPLICATIONS

WBSCR17 siRNA (m) is recommended for the inhibition of WBSCR17 expression in mouse cells.

## SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor WBSCR17 gene expression knockdown using RT-PCR Primer: WBSCR17 (m)-PR: sc-155246-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.